저자: JamieDimon · 외국인
요약 보기
2026년 2분기 투자 전략으로 마이크로소프트, 유나이티드헬스, JPMorgan, 애플, 존슨앤드존슨, 엔비디아, 버크셔해서웨이 7개 종목을 제시. 인플레이션 3.2%, 성장률 둔화(2.1%) 등 거시 환경 속 기업 간 격차 확대를 근거로 들며, 분할 매수와 종목별 3~7% 비중 배분을 권고. 자막 기준 발언이며 제목은 'Buy Before May' 취지.
다듬은 글
As we enter the second quarter of 2026, I'm getting the same question from institutional clients, individual investors, and financial media, which specific stocks should we be buying right now? It's a direct question that deserves a direct answer, and after managing over 4.1 trillion in assets at JPMorgan Chase and navigating five decades of market cycles, I have very clear conviction about where investors should be positioned for Q2.
Let me be upfront about my approach. I don't make stock recommendations lightly or frequently. When I identify specific companies worth buying, it's based on rigorous fundamental analysis, deep understanding of competitive dynamics, and conviction that these businesses will outperform regardless of broader market conditions.
The stocks I'm recommending today represent our highest conviction ideas for Q2 2026 based on proprietary research and insights that only come from managing money at institutional scale. The macro environment for Q2 presents both opportunities and risks that most investors are misreading. Inflation remains above Fed targets at 3.2% but economic growth is slowing to approximately 2.1% annually.
Corporate earnings are growing but at a decelerating pace that's creating significant dispersion between high-quality companies and average performers. Interest rates are likely to remain elevated which benefits certain sectors while punishing others. Most importantly, we're seeing the early stages of what I call the great corporate separation, the widening gap between nd those without them.
In this environment, stock picking becomes crucial. Index investing and broad diversification won't generate the returns needed to build wealth. Instead, investors need concentrated positions in exceptional companies trading at reasonable valuations. Today, I'm sharing our seven highest conviction stock picks for Q2 2026.
These recommendations represent months of analysis by our research teams and reflect investments we're making with our own institutional capital. Each of these companies meets our criteria for sustainable competitive advantages, strong balance sheets, experienced management teams, and reasonable valuations relative to long-term growth prospects.
Microsoft Corporation, the AI infrastructure winner, Microsoft represents our top technology recommendation for Q2 2026 and is not close. While other technology companies are struggling to monetize artificial intelligence investments, Microsoft has already built AI into a profitable, sustainable business model that's generating billions in incremental revenue.
The company's competitive position in AI stems from three key advantages. First, Microsoft's partnership with OpenAI provides exclusive access to the most advanced large language models, which the company has integrated into every major product line. Office 365 Copilot is generating substantial subscription revenue increases with enterprise customers paying premium prices for AI-enhanced productivity tools.
Second, Microsoft's Azure cloud platform is becoming the preferred infrastructure for enterprises deploying AI applications. The company's AI services revenue grew 87% year-over-year in the most recent quarter, and we expect this growth to accelerate as enterprises move beyond pilot programs to production AI implementations.
Third, Microsoft's software ecosystem creates powerful network effects that become stronger as AI capabilities improve. Companies using Microsoft productivity software, cloud infrastructure, and AI tools become increasingly locked into the ecosystem, providing predictable recurring revenue streams with high switching costs.
Our analysis suggests Microsoft's AI business could generate $15-20 billion in annual revenue by 2027, representing incremental profits that aren't fully reflected in current valuations. The stock trades at approximately 28 times forward earnings, which appears reasonable given the company's AI-driven growth trajectory and 40% plus operating margins.
We recommend accumulating Microsoft shares during any Q2 weakness with a target allocation of 5-7% for growth-oriented portfolios. The company's combination of AI leadership, cloud infrastructure dominance, and software ecosystem lock-in provides multiple decades of competitive advantage. UnitedHealth Group, demographic inevitability, UnitedHealth Group represents our top healthcare recommendation and one of our highest conviction picks across all sectors.
The company benefits from the most powerful demographic trend in American history, the aging of 76 million baby boomers who consume healthcare services at rates three four times higher than younger populations. UnitedHealth's competitive advantage stems from vertical integration across the healthcare value chain.
The company combines health insurance, pharmacy benefits management, and direct healthcare delivery through its Optum division. This integration allows UnitedHealth to control costs while capturing profits at multiple points in the healthcare system. The financial results speak for themselves. UnitedHealth has grown revenues at 13% annually over the past five years while expanding operating margins from 6.2% to 8.4%.
The company generates over $22 billion in annual free cash flow and returns substantial . More importantly, UnitedHealth's growth trajectory is accelerating rather than slowing. The company's Medicare Advantage membership is growing at 10% a less annually as baby boomers age into Medicare eligibility.
Optum's healthcare services division is gaining market share from traditional fee-for-service healthcare delivery, generating higher margins while improving patient outcomes. Our demographic analysis suggests UnitedHealth's addressable market will grow by 60-80% over the next decade as the 65 plus population increases from 56 million to over 90 million Americans.
The company's integrated model provides sustainable competitive advantages in capturing this growth while maintaining pricing power. UnitedHealth trades at 24 times forward earnings, which represents reasonable valuation for a company with 10% plus long-term revenue growth, expanding margins, and defensive business characteristics.
We recommend target allocations of 4-6% for conservative portfolios and 3-5% for growth-oriented strategies. JPMorgan Chase, financial strength in uncertain times. As CEO of JPMorgan Chase, I have unique insight into our competitive position and long-term prospects. While I'm obviously biased, our institutional research team evaluates JPMorgan objectively and consistently rates it as our top financial services recommendation.
JPMorgan's competitive advantages start with balance sheet strength and risk management capabilities that are unmatched in the banking industry. The company maintains Tier 1 capital ratios above 15%, loan loss provision coverage exceeding historical averages, and diversified revenue streams that perform well across different economic scenarios.
The current interest rate environment strongly benefits JPMorgan's profitability. Net interest margins have expanded from 2.3% to 3.8% as the Federal Reserve raised rates, generating billions in additional net interest income. Our asset liability management ensures that rising rates provide more benefit than harm to profitability.
Beyond traditional banking, JPMorgan generates substantial revenue from investment banking, asset management, and trading operations that benefit from market volatility and corporate activity. The company's global reach and client relationships provide competitive advantages in winning mandates and capturing market share during economic uncertainty.
JPMorgan's technology investments position the company for continued market share gains in digital banking, payment processing, and financial services. The company spends over $12 billion annually on technology, more than most pure technology companies while maintaining cost discipline across other operational areas.
The stock trades at 12 times forward earnings with a 3.1% dividend yield, representing attractive valuation for the highest quality bank in the world. We expect JPMorgan to generate 12-15% annual returns through a combination of earnings growth, dividend increases, and share repurchases. Investors should view JPMorgan as a defensive growth stock that provides portfolio stability while participating in economic expansion.
Target allocations of 3-5% are appropriate for most investment strategies. Apple Inc., innovation and capital return excellence. Apple represents our preferred consumer technology investment combining brand loyalty, innovation capabilities, and exceptional capital allocation in a business model that generates extraordinary cash flows and returns to shareholders.
The company's competitive moat stems from the integrated ecosystem of hardware, software, and services that creates high switching costs and recurring revenue streams. iPhone users typically remain loyal to the Apple ecosystem, purchasing additional products and subscribing to services that generate higher margin revenue.
Apple's services business, including the App Store, iCloud, Apple Music, and other subscriptions, now generates over $85 billion in annual revenue with gross margins exceeding 70%. This recurring revenue stream provides stability and growth that complements cyclical hardware sales. The company's innovation pipeline remains strong despite skepticism about new product categories.
Apple's augmented reality capabilities, health technology integration, and artificial intelligence applications provide multiple avenues for future growth and ecosystem expansion. Most importantly, Apple's capital allocation strategy creates substantial shareholder value through aggressive share repurchase and dividend growth.
The company has reduced share count by over 35% since 2012 while growing dividends at 7% annually, returning over $500 billion to shareholders. Apple's balance sheet strength provides flexibility for strategic acquisitions, increased capital returns, and investment growth opportunities. The company maintains over $160 billion in cash and marketable securities while generating $100 plus billion in annual free cash flow.
Current valuation appears reasonable at 26 times forward earnings considering Apple's 33% operating margins, strong competitive position, and capital return program. We recommend accumulating Apple shares during Q2 weakness with target allocations of 4 6% for growth portfolios. Johnson & Johnson pharmaceutical innovation and dividend growth.
Johnson & Johnson represents our top pharmaceutical recommendation combining patent protected drug portfolio with medical device innovation and consumer product stability. The company provides defensive characteristics while participating in healthcare sector growth driven by demographic trends. J&J's pharmaceutical division focuses on oncology, immunology, and neuroscience therapeutic areas with strong patent protection, limited generic competition, and growing patient populations.
The company's drug pipeline includes 60 plus programs in late stage development providing visibility into future revenue growth. The medical device business benefits from aging populations requiring more surgical procedures, diagnostic tests, and medical interventions. J&J's device portfolio spans multiple specialties with leading market positions and innovative product pipelines.
Consumer products provide stable cash flows and global distribution advantages that support the overall business model. While consumer growth is modest, this division generates consistent profits that fund pharmaceutical research and development. J&J's dividend track record is unmatched among large corporations with 61 consecutive years of dividend increases including payments throughout multiple recessions and market cycles.
Current dividend yield of 2.9% provides income while dividend growth of 5 6% annually provides inflation protection. The company's balance sheet strength supports continued innovation investment strategic acquisitions while maintaining dividend growth. J&J maintains AAA credit ratings and generates predictable cash flows that exceed dividend requirements by substantial margins.
Trading at 16 times forward earnings, J&J offers attractive valuation for a pharmaceutical company with patent protected revenue streams and defensive business characteristics. Target allocations of 3 4% provide portfolio stability and dividend income. Nvidia Corporation semiconductor leadership despite valuation.
Nvidia remains our semiconductor recommendation despite elevated valuation reflecting the company's dominant position in artificial intelligence computing and data center infrastructure. While the stock appears expensive on traditional metrics, Nvidia's competitive advantages and addressable market growth justify premium valuation.
The company's graphics processing units have become essential infrastructure for artificial intelligence training and inference applications. Nvidia's CUDA software platform creates switching costs and developer loyalty that protect market share even as competitors attempt to challenge the company's position.
Data center revenue now exceeds gaming revenue as enterprises deploy AI applications requiring Nvidia's specialized computing capabilities. This transition provides more predictable revenue streams with higher margins than consumer gaming applications. Nvidia's competitive moat includes not just superior hardware performance but software ecosystems, developer tools, and technical support that create comprehensive solutions for enterprise customers.
Competitors can replicate individual products but struggle to match Nvidia's complete platform approach. The company's financial performance reflects these competitive advantages. Revenue grew 126% in the most recent quarter while gross margins expanded to over 70%. Free cash flow generation supports aggressive research and development spending while returning capital to shareholders.
Despite trading at 45 times forward earnings, Nvidia's revenue growth trajectory and market position justify premium valuation for growth oriented investors. We recommend modest allocations of 2 3% given valuation concerns but recognize the company's potential for continued outperformance. Berkshire Hathaway Warren Buffett's enduring value.
Berkshire Hathaway represents our top conglomerate recommendation providing exposure to Warren Buffett's investment acumen and a diversified portfolio of wholly owned businesses and equity investments. Berkshire's competitive advantages include permanent capital that allows long-term investment thinking, operational excellence across diverse business units, and Warren Buffett's track record of value creation spanning over five decades.
The company's insurance operations provide low cost capital that funds investment activities and business acquisitions. GEICO, General Re, and other insurance subsidiaries generate underwriting profits while providing investment float for portfolio management. Wholly owned businesses include BNSF Railway, Berkshire Hathaway Energy, and dozens of manufacturing and service companies that generate consistent cash flows and benefit from operational improvements and strategic guidance.
The equity portfolio includes major positions in Apple, Bank of America, Coca-Cola, and other high quality companies selected for long-term value creation rather than short-term trading profits. Berkshire's decentralized management structure and strong corporate culture should provide continuity in performance even as Warren Buffett and Charlie Munger transition leadership responsibilities to the next generation.
Trading at 1.4 times book value, Berkshire offers reasonable valuation for a company with above average returns on equity and strong competitive positions across multiple industries. Target allocations of 3 5% provide portfolio diversification and exposure to value investing principles. Implementation strategy and risk management.
These seven stock recommendations should be implemented gradually over Q2 2026 rather than purchased simultaneously. Market volatility provides opportunities to accumulate positions at attractive prices while avoiding the risk of poor timing on large purchases. We recommend dollar cost averaging into these positions over 60 90-day periods taking advantage of daily volatility to improve entry points.
This approach reduces timing risk while ensuring participation in long-term value creation. Position sizing should reflect individual risk tolerance and portfolio objectives, but we generally recommend maximum individual position sizes of 5 7% for even our highest conviction recommendations. Diversification remains important even when investing in exceptional companies.
Risk management requires ongoing monitoring of fundamental business performance rather than short-term stock price movements. These companies should be held for multiple years unless fundamental business conditions deteriorate substantially. Rebalancing should occur quarterly or when a position becomes significantly overweight due to performance.
The goal is maintaining strategic allocations while allowing successful investments to compound over time. Tax considerations should influence implementation timing and account location decisions. These recommendations are suitable for both taxable and tax advantage accounts with specific structures depending on individual circumstances.
Our Q2 2026 stock recommendations reflect conviction with sustainable competitive advantages, experienced management teams, and reasonable valuations relative to long-term growth prospects. These investments should provide attractive returns while preserving capital during uncertain market conditions.
The key to successful stock investing remains patience, discipline, and focus on business fundamentals rather than market movements. These seven companies represent our best ideas for building wealth through equity ownership in an increasingly complex investment environment.
Comments 0